



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

7 August 2020

A\$5 million Capital Raising to Support Growth

- **G Medical secures A\$5m investment from institutional and professional investors at \$0.05 per share**
- **Capital raised will be specifically deployed to scale up IDTF operations, expand the Company's sales team in the USA and fund manufacturing costs for growing Prizma and G Medical Patch purchase orders**

Medical device and telehealth company **G Medical Innovations Holdings Ltd (ASX: GMV)** ("G Medical" or "Company") is pleased to advise that it has received firm commitments from institutional and professional investors to raise A\$5 million through the issue of 100,000,000 fully paid ordinary shares in the Company ("Shares") at an issue price of \$0.05 per Share ("Placement"). MST Financial acted as sole lead manager and bookrunner to the Placement.

G Medical is encouraged by this strategic investment from investors and intends to utilise the funds raised to rapidly scale up its Independent Diagnostic Testing Facility (IDTF) operations, expand the Company's sales team in the United States and increase manufacturing volumes of the Prizma device and G Medical Patch to fulfill anticipated purchase orders.

Management commentary

CEO Dr Yacov Geva, said: *"This strategic investment from professional and institutional investors represents a strong vote of confidence in our growth strategy. They recognise the potential of our IDTF operations in the United States, particularly as we gain traction with more hospitals there, and they understand that we can build complementary revenue streams through medical device sales. They are also attracted to the prospects for telehealth in the current market and G Medical's established infrastructure."*

"We now have the financial capacity to fast-track IDTF's growth and fund greater manufacturing volumes for the Prizma and the Patch in anticipation of more purchase orders. We will provide shareholders with an update as these matters progress"

It is anticipated that the Company will issue the Shares in respect to the Placement on or about 13 August 2020. The Company intends to issue the Shares in respect to the Placement pursuant to the shareholder approval obtained by the Company on 16 July 2020. However, if the issue price of Shares pursuant to the Placement (being \$0.05 per Share) is less than 80% of the average market price of Shares calculated over the last 5 days on which sales in Shares are recorded before the day on which the issue is made, the Shares in respect to the Placement will be issued pursuant to the Company's existing Listing Rule 7.1 capacity. Refer to the Appendix 3B which will accompany this announcement for further details.

Ends

Authorised for release by Yacov Geva, Managing Director.

For more information, please contact:

Brendan De Kauwe
Director
Brendan@gmedinnovations.com

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 (0) 431 271 538

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and telehealth solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' smartphone compatible medical device is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.